Research article · 2 Apr 2018
OtherPublished 22 Jul 2016
Ofatumumab for the treatment of chronic lymphocytic leukemia
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Over the last few years, several new monoclonal antibodies (mAbs) directed against lymphoid cells have been developed and investigated in chronic lymphocytic leukemia (CLL). Two mAbs have been demonstrated to have the most important clinical value in patients with CLL – rituximab, which targets the CD20 antigen, and alemtuzumab, which is active against the CD52 antigen. Recently, several new mAbs have been explored and evaluated in preclinical studies and in early clinical trials. One of these is ofatumumab (HuMax-CD20™), a fully human monoclonal immunoglobulin (Ig)G1-k antibody targeting a CD20 molecule on B cells. Ofatumumab specifically recognizes an epitope encompassing both the small and large extracellular loops of CD20, distinct from the epitope recognized by rituximab. Ofatumumab, in comparison with rituximab, shows superiority in complement-dependent cytotoxicity of B cells, and does not induce cell death of tumor B cells by apoptosis. In a Phase I/II study, ofatumumab demonstrated significant depletion of CD19+/CD5+ CLL cells, and showed a favorable safety profile in previously treated CLL patients. A recent study demonstrates the effectiveness of ofatumumab in patients with fludarabine-refractory CLL. Ofatumumab potentially represents an active treatment option with clinical benefit for patients with very poor prognosis who have exhausted standard treatment options. In December 2004, the US FDA granted Fast Track status for the use of ofatumumab in therapy of CLL in patients who failed treatment with fludarabine.
Subjects
General & Internal MedicineAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Research article · 4 May 2021
Investigation of 13q14.3 Deletion by Cytogenetic Analysis and FISH Technique and miRNA-15a and miRNA-16-1 by Real Time PCR in Chronic Lymphocytic Leukemia
Research article · 2018
Lack of Association of Human Herpesvirus 6 (hHV-6) with Chronic Lymphocytic Leukemia and Leukemic Low-Grade B-Cell Lymphomas
Research article · 2018
Role of Prognostic Nomogram and Survival Index in Prognosis and the Outcome of Patients with Chronic Lymphocytic Leukemia - A Single Center Experience
Commentary · Oct 2013
Novel vaccine technique shows promise in Phase I trial of advanced chronic lymphocytic leukemia
More from this journal
The newest in Clinical Practice.
Article · 20 May 2025
Histological effects of doxorubicin and baobab plants on some organs of rat
Article · 20 May 2025
Histological effects of doxorubicin and baobab plants on some organs of rat
Article · 28 Mar 2025
Using
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalClinical Practice
- SubjectGeneral & Internal Medicine
- BylineArticles whose byline prints “Tadeusz Robak”
